Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence
Krishna Sriram, Paul A. Insel
doi: https://doi.org/10.1101/2020.03.25.20043927
Krishna Sriram
*Departments of Pharmacology, University of California San Diego, La Jolla, California 92093, USA
Ph.D.Paul A. Insel
*Departments of Pharmacology, University of California San Diego, La Jolla, California 92093, USA
^Departments of Medicine, University of California San Diego, La Jolla, California 92093, USA
M.D.Data Availability
There are no underlying data to report, this is a review of data in the literature, cited where appropriate.
Posted April 20, 2020.
Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence
Krishna Sriram, Paul A. Insel
medRxiv 2020.03.25.20043927; doi: https://doi.org/10.1101/2020.03.25.20043927
Subject Area
Subject Areas
- Addiction Medicine (316)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2298)
- Dermatology (202)
- Emergency Medicine (371)
- Epidemiology (11623)
- Forensic Medicine (10)
- Gastroenterology (683)
- Genetic and Genomic Medicine (3629)
- Geriatric Medicine (341)
- Health Economics (622)
- Health Informatics (2332)
- Health Policy (919)
- Hematology (336)
- HIV/AIDS (758)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (394)
- Neurology (3390)
- Nursing (193)
- Nutrition (512)
- Oncology (1777)
- Ophthalmology (526)
- Orthopedics (211)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1013)
- Primary Care Research (410)
- Public and Global Health (6021)
- Radiology and Imaging (1238)
- Respiratory Medicine (814)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (143)